Publication: Dengue and the lectin pathway of the complement system
6
Issued Date
2021-07-01
Resource Type
ISSN
19994915
Other identifier(s)
2-s2.0-85109151022
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Viruses. Vol.13, No.7 (2021)
Suggested Citation
Romchat Kraivong, Nuntaya Punyadee, M. Kathryn Liszewski, John P. Atkinson, Panisadee Avirutnan Dengue and the lectin pathway of the complement system. Viruses. Vol.13, No.7 (2021). doi:10.3390/v13071219 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77266
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Dengue and the lectin pathway of the complement system
Abstract
Dengue is a mosquito-borne viral disease causing significant health and economic burdens globally. The dengue virus (DENV) comprises four serotypes (DENV1-4). Usually, the primary infection is asymptomatic or causes mild dengue fever (DF), while secondary infections with a different serotype increase the risk of severe dengue disease (dengue hemorrhagic fever, DHF). Complement system activation induces inflammation and tissue injury, contributing to disease pathogenesis. However, in asymptomatic or primary infections, protective immunity largely results from the complement system’s lectin pathway (LP), which is activated through foreign glycan recognition. Differences in N-glycans displayed on the DENV envelope membrane influence the lectin pattern recognition receptor (PRR) binding efficiency. The important PRR, mannan binding lectin (MBL), mediates DENV neutralization through (1) a complement activation-independent mechanism via direct MBL glycan recognition, thereby inhibiting DENV attachment to host target cells, or (2) a complement activation-dependent mechanism following the attachment of complement opsonins C3b and C4b to virion surfaces. The serum concentrations of lectin PRRs and their polymorphisms influence these LP activities. Conversely, to escape the LP attack and enhance the infectivity, DENV utilizes the secreted form of nonstructural protein 1 (sNS1) to counteract the MBL effects, thereby increasing viral survival and dissemination.